natgillin/translations-raw huggingface dataset:
A medical device, comprising an IL-6 antibody according to any of claims 1-4, wherein said device is suitable for contacting or administering said IL-6 antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of an IL-6 antibody according to any of claims 1-4. 
Proizvodni predmet pogodan za farmaceutsku ili dijagnostičku upotrebu kod ljudi, koji se sastoji od ambalaže i bočice koja sadrži otopinu ili liofilizirani oblik anti IL-6 protutijela prema bilo kojem od zahtjeva 1-3, proizvoljno pri čemu je navedeni spremnik komponenta parenteralne, supkutane, intramuskularne, intravenozne, intrartikularne, intrabronhijalne, intraabdominalne, intrakapsularne, intrahrskavične, intrakavitarne, intracelijalne, intracerebelarne, intracerebroventrikularne, intrakolične, intracervikalne, intragastrične, intrahepatične, intramiokardijalne, intraostealne, intrapelvične, intraperikardijalne, intraperitonealne, intrapleuralne, intraprostatske, intrapulmonalne, intrarektalne, intrarenalne, intraretinalne, intraspinalne, intrasinovijalne, intratoraksne, intrauterine, intravezikalne, intralezionalne, bolusne, vaginalne, rektalne, bukalne, sublingvalne, intranazalne, ili transdermalne naprave ili sustava za isporuku.
(A2a) a phenyl-substituted lower alkenyl group having a halogen-substituted lower alkoxy group(s) as a substituent(s) on a phenyl group, or (A2b) a halogen-substituted phenyl group; and n represents an integer of 1 to 6. 
(A2a) fenil-supstituiranu skupinu niži alkenil s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (supstituentima) na fenilnoj skupini, ili (A2b) halogen-supstituiranu fenilnu skupinu); a n predstavlja cijeli broj od 1 do 6.
A tablet comprising a composition comprising crystalline apixaban particles having a mean particle size equal to or less than about 85 µm and a D90 equal to or less than 85 µm and further comprising a pharmaceutically acceptable diluent or carrier. 
Tableta ili kapsula koja sadrži farmaceutsku kompoziciju, gdje farmaceutska kompozicija sadrži apiksaban i farmaceutski prihvatljiv razrijeđivač ili nosač, gdje je apiksaban u obliku tvari i kristalnom obliku i pojedinačne tvari apiksabana, bilo da tvari postoje zasebno ili u aglomeratu, imaju D90 jednak ili manji od 89 µm kao što je mjereno raspršivanjem laserske svjetlosti.
Use of a nucleic acid molecule comprising a nucleic acid sequence, which codes for a plant pentose transporter, for the transformation of a cell, wherein the transformation enables the cell to take up L-arabinose, wherein the cell is a yeast cell, and wherein the plant pentose transporter originates from Arabidopsis and comprises an amino acid sequence, which is at least 70%, preferably at least 80%, more preferably at least 90% identical to the amino acid sequence of SEQ ID NO: 1 and has an in vitro and/or in vivo pentose transport function, or functional equivalents of SEQ ID NO: I having an in vitro and/or in vivo pentose transport function. 
HR P20171423 T1 PATENTNI ZAHTJEVI Upotreba molekule nukleinske kiseline koja sadrži nukleinskokiselinski slijed, koji kodira biljni transporter pentoza, naznačena time što je molekula nukleinske kiseline namijenjena transformiranju stanice, gdje transformiranje omogućuje unos L-arabinoze u stanicu, gdje je stanica stanica kvasca, te gdje biljni transporter pentoza ima aminokiselinski slijed koji je najmanje 70%, po mogućnosti najmanje 80%, poželjnije najmanje 90% istovjetan aminokiselinskom slijedu SEQ ID NO: 1 i in vitro ifili in vivo ima funkciju transporta pentoza.
A method according to any preceding claim, wherein the step of mixing the slurry further comprises adding a surface agent. 
Postupak u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačen time što korak miješanja mulja dodatno obuhvaća dodavanje površinski aktivnog sredstva.
represents [1] a hydrogen atom, or [2] a 4- to 10-membered heterocycloalkyl group which may be substituted by 4- to 10-membered heterocycloalkyl group(s)]. 
R'" predstavlja [1] atom vodika ili [2] 4- do 10-eročlanu heterocikloalkilnu skupinu, koju može biti supstituirana s jednom ili više 4- do 10-eročlanih heterocikloalkilnih skupina].
A stably transformed or transfected recombinant host cell comprising a first vector comprising a polynucleotide of SEQ. 
Stabilno transformirana ili transficirana rekombinantna stanica-domaćin, naznačena time što sadrži prvi vektor, koji sadrži polinukleotid sa SEQ.
The polypeptide of claim 1 wherein Mp is a biologically active fragment of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, or 18; or Mp has the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, or 18. 
Polipeptid prema zahtjevu 1 naznačen time da Mp je biološki aktivni dio iz SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, ili 18; ili Mp ima amino kiselinsku sekvencu prikazanu u SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, ili 18.
The resulting solid is dissolved in hot water (150 ml) and adjusted to pH 3-4 using 6M HCl. 
Dobivenu krutu tvar se otopi u vrućoj vodi (150 ml) i podesi se na pH 3-4 upotrebom 6M HCL.
The device for producing the sodium hypochlorite or hypochlorous acid according to claim 1, wherein the electrodes of each electrolytic cell are in the form of plates between which a circulating current of low continuous voltage reverses direction regularly, at a fixed time period, during usage of the device. 
Uređaj (40) za proizvodnju natrijevog hipoklorita ili hipoklorne kiseline prema patentnom zahtjevu 1, naznačen time što se elektrode (28, 29) koje su u obliku ploča mogu polarizirati u oba smjera u vremenskim intervalima u rasponu od 90 minuta do 180 minuta ovisno o tvrdoći vode.
This shows that an increasing amount of RME softens the films and shifts the Tg's to lower values and that the amount of RME can be used as a tool to adjust the Tg of the cured coating. 
To pokazuje da povećanje količine RME-a omekšava filmove i pomiče Tg prema nižim vrijednostima i da se količina RME-a može upotrijebiti kao sredstvo za namještanje Tg vrijednosti otvrdnute prevlake.
The combined organic layers are washed with brine and dried (magnesium sulfate). 
Spojeni organski slojevi se isperu otopinom soli i smjesa se suši (magnezijev sulfat).
The pharmaceutical composition according to claim 23, comprising 175 mg of Capecitabine, 50.06 mg of Lactose Anhydrous, 5.00 mg of Hypromellose, 52.50 mg of Crospovidone, 125.00 mg of Pharmaburst C, 32.50 mg of Mannitol, 65.54 mg of Microcrystalline Cellulose, 11.50 mg of Magnesium Stearate, 21.75 mg of Aspartame, 4.50 mg of Saccharin Sodium, 11.00 mg of Vanillin, 2.06 mg of Bittermasking Blend and 4.15 mg of Strawberry Flavor. 
Farmaceutski sastav prema zahtjevu 23, naznačen time, da sadrži 175 mg kapecitabina, 50,06 mg bezvodne laktoze, 5,00 mg hipromeloze, 52,50 krospovidona, 125,00 farmabursta C, 32,50 mg manitola, 65,54 mg mikrokristalinične celuloze, 11,50 mg magnezij stearata, 21,75 mg aspartama, 4,50 mg natrij saharina, 11,00 mg vanilije, 2,06 mg smjese za maskiranje gorčine i 4,15 mg arome jagode. HR P20110113 TI .
A method for controlling HIV infection in a mammalian subject with AIDS comprising administering an effective amount of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to said mammalian subject 
Forbolski ester Formule II: rormusa li ili njegova farmaceutski prikladna sol, izomer, enantiomer, solvat, hidrat ili polimorf za uporabu u prevenciji ili liječenju HIV infekcije u subjekta koji je sisavac.
The reaction mixture was heated at 85 °C. After the reaction was complete, it was diluted with ethyl acetate, washed with 1N NaOH, brine and dried over anhydrous Na2SO4. The solution was filtered and concentrated in vacuo. 
Reakcijska smjesa se zagrijava na 85% C. Nakon završetka reakcije, razrijedi se etil acetatom, ispere IN NaOH, otopinom soli i suši iznad anhidridnog Na,SOy. otopina se flitrira i koncentrira in vacuo.
The antibody molecule of claim 3 having a heavy chain comprising SEQ ID NO: 40, and a light chain comprising SEQ ID NO: 35. 
Molekula protutijela prema zahtjevu 3, naznačena time, da ima jaki lanac koji obuhvaća SEQ ID NO:40, 1 slabi lanac koji obuhvaća SEQ ID NO:35.
The method of claim 1, wherein the compound is administered in the form of a gel. 
Spoj za uporabu za liječenje kožne poremećaja kod pacijenta, naznačen time da se spoj primjenjuje topikalno, pri čemu
In another embodiment the invention CNS 7056 is provided in a container for pharmaceutical use comprising 10 mg of CNS 7056, preferably in a concentration of 1 mg/ml, e.g. a vial, ampoule, syringe or the like. 
CNS 7056 ili njegova sol ili solvat radi primjene sukladno bilo kojem od gornjih zahtjeva, koji je u obliku spremnika za farmaceutsku uporabu koji sadrži 10 mg CNS7056 ili njegove soli ili solvata, a prvenstveno u koncentraciji od 1 mg/ml.
A process according to any one of claims 1 to 8 wherein the reaction mixture under a) is seeded with seeds of the salt of (aS,BR)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-B-phenyl-3-quinolineethanol and the resolution agent as defined in any one of claims 1, 2 or 3 before and after adding the resolution agent to the reaction mixture. 
Postupak prema bilo kojem od zahtjeva 1 do 8 naznačen time da reakcijska smjesa iz a) je zametnuta sa zametcima soli (aS,BR)-6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-B-fenil-3-kinolinetanola i sa sredstvom za razlučivanje kako je definirano u bilo kojem od zahtjeva 1, 2 ili 3 prije i nakon dodavanja sredstva za razlučivanje u reakcijsku smjesu.
Wind system (1) according to claim 4, characterised in that said systems that actuate said spoiler receive commands in wireless mode from said smart control system. 
Vjetreni sustav (1) prema zahtjevu 4, naznačen time da spomenuti sustavi koji pokreću spojler primaju komande bežičnim putem 1z spomenutog pametnog kontrolnog sustava.
A fragment of FliD is preferably a fragment of FliD, preferably of full-length FliD, whereby the fragment has an amino acid sequence which is long enough so as to allow a person skilled in the art to identify the fragment to be a fragment of FliD and full-length FliD in particular and to exclude that the fragment is a fragment of a protein or polypeptide different from FliD and full-length FliD in particular. 
Uporaba kompleta koji sadrži FUlD ili njegov fragment i najmanje jedan daljnji sastojak, u postupku sukladno bilo kojem od zahtjeva 1 do 6, naznačen time da fragment ima aminokiselinsku sekvencu koja je dovoljno duga da se identificira fragment koji je fragment FliD i isključi da je fragment fragment proteina 111 polipeptidđa koji je različit od FliD 1 pri čemu je barem jedan daljnji sastojak odabran iz skupine koja se sastoji od pufera, čvrste faze i upute za uporabu.
The injectable preparation according to claim 4, wherein the meglumine salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a hydrate thereof is an amorphous product. 
Injekcijski pripravak u skladu s patentnim zahtjevom 4, naznačen time, daje megluminska sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida ili hidrat istog amorfan produkt.
In one embodiment, the second therapeutic agent is selected from quinidine, quinidine sulfate, LBH589 (Novartis), oxycodone, and gabapentin. 
Sastav iz patentnog zahtjeva 11, pri čemu je drugi terapijski agens odabran između kinidina, kinidin sulfata, oksikodona i gabapentina.
the amino acid at heavy chain amino acid position 103 is Valine (V); and 
(b) na aminokiselinskoj poziciji 103 jakog lanca, odabire aminokiselina valin (V); i
comparing the biological effect of said sample with the biological effect of a reference sample; 
uspoređivanja biološkog učinka rečenog uzorka s biološkim učinkom referentnog uzorka;
A polymorph according to any one of claims 1 to 12 for use in the treatment of anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory disorders, Parkinsons Disease, ADHD, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, stroke and also disorders associated with spinal trauma and/or head injury, IBS or obesity. 
Polimorf prema bilo kojem od patentnih zahtjeva 1 do 12 namijenjen upotrebi u liječenju anksioznosti, depresije, epilepsije, opsesivno-kompulzivnih poremećaja, migrene, poremećaja kognitivnog pamćenja, Parkinsonove bolesti, ADHD, poremećaja spavanja, poremećaja hranjenja, poput anoreksije i bulimije, napadaja panike, ustezanja od zloupotrebe narkotika, poput kokaina, etanola, nikotina i benzodiazepina, shizofrenije, inzulta, a također 1 poremećaja povezanih s ozljedama kralježnice i(li) glave, IBS ili pretilosti.
This provides the possibility of opening and dosing the packaging like a book with an angle of more than 180°, preferably 240°, which is essential in order to be packed in automated packing machines, which require that the two sides of the packaging must be opened like a book within an angle of more than 180°, preferably 240°. 
To osigurava mogućnost otvaranja i zatvaranja pakiranja kao knjige pod kutom koji je veći od 180", poželjno 240%, što je važno da bi se obavilo pakiranje u automatiziranim strojevima za pakiranje i što zahtjeva da dvije strane pakiranja moraju biti otvorene kao knjiga pod kutom koji je veći od 180", poželjno 240".
The following borolanes, borinanes and diboronic acid derivatives are preferred: wherein Ra, Rb, Rc, Rd, Re and Rf represent independently of each other a substituted or unsubstituted, linear or branched alkyl group with 1 to 10 carbon atoms or cycloalkyl group with 3 to 10 carbon atoms. 
ov o pri čemu R, R", R%, R", R" R"i RI! predstavljaju nezavisno jedan od drugog supstituiranu ili nesupstituiranu, linearnu ili razgranatu alkilnu grupu s 1 do 10 ugljikovih atoma ili cikloalkilnu grupu s 3 do 10 ugljikovih atoma.
The volatiles were evaporated off, and the crude material was dried in vacuo. 
Hlapivi dio je uparen, a sirovi materijal je osušen in vacuo.
Threading device according to claim 3 or 4, characterized in that the threading device further comprises a plurality of toothed wheels (31, 32) adapted to transfer the movement of the beam (18; 118) to the arc-shaped element. 
Naprava za uvođenje užeta oko alke prema zahtjevu 3 ili 4, naznačena time da naprava za uvođenje užeta dodatno sadrži veći broj nazubljenih kotača (31, 32) koji su prilagođeni da prenose pomicanje letve (18; 118) na element u obliku luka.
The resulting ethyl acetate solution was then dried, diluted with ether (2 1.) and then treated with excess gaseous hydrogen chloride to give a gelatinous suspension which crystallized overnight. 
Dobivena etilacetatna otopina se tada suši, razblaži se sa eterom (2 1) i tada se tretira sa viškom plinovitog klorovodika tako da se dobivana želatinozna suspenzija koja preko noći iskristalizira.
instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation. 
upute za (i) uporabu otopine ili (ii) rekonstituciju i/ili uporabu liofilizirane formulacije.
A peptide linker typically has a length of 1 to 10 amino acids, preferably 1 to 5, even more preferably 1 to 3 amino acids, in some cases the linker sequence may be even longer comprising 11 to 50 amino acids. 
Fuzijski peptid prema patentnom zahtjevu 6, naznačen time da vezivna sekvenca ima duljinu od 1 do 10 aminokiselina.
In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) of formula (A); wherein 
(a) molekulu s dvolančanom kratkom interferirajućom nukleinskom kiselinom (siNA) u skladu s patentnim zahtjevom 1;
The process of claim 1 or claim 2, further comprising providing a third web having a series of parallel grooves, the grooves having a three-sided polygonal cross section, and arranging the third web adjacent to the second web so as to provide a second series of individual pockets having a hexagonal cross section. 
Postupak prema zahtjevima 1 ili 2, koji dalje podrazumijeva osiguravanje treće mreže s nizom paralelnih žljebova s poligonalnim trostranim poprečnim presjekom 1 raspoređivanje treće mreže neposredno do druge mreže kako bi se dobio drugi niz pojedinačnih džepova šesterokutnog poprečnog presjeka.
Preferably, above about 2 weight percent, more preferably above about 15 weight percent, and most preferably above about 20 weight percent of the aerosol former carried on the aerosol generating means is delivered to the user as WTPM. 
Poželjno se iznad oko 2 masena postotka, još poželjnije iznad oko 15 masenih postotaka, i najpoželjnije iznad oko 20 masenih postotaka formirača aerosola koji sadrži sredstvo za generiranje aerosola provodi korisniku kao MUČM (mokra ukupna čestična materija).
is selected from the group consisting of hydrogen and C1-6alkyl; 
je izabran iz grupe koju čine vodik i C1-6 alkil;
The cladribine may be for use in the treatment of a patient known to be NMO-IgG seropositive. 
Pripravak, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 8 u liječenju ili ublažavanju NMO kod pacijenta za kojeg se zna da je seropozitivan na NMO-IgG.
wherein the valve is arranged such that the valve member can be rotated into: 
gdje je ventil izveden tako da element (300) ventila može biti rotacijom doveden u:
The method of any one of the preceding claims, wherein the first nucleotide sequence encoding the chimeric human/rodent MHC II a polypeptide is expressed under regulatory control of endogenous rodent MHC II a promoter and regulatory elements and/or the second nucleotide sequence encoding the chimeric human/rodent MHC II B polypeptide is expressed under regulatory control of endogenous rodent MHC II B promoter and regulatory elements. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se prva nukleotidna sekvenca koja kodira kimerni ljudski/glodarski MHC II-a-polipeptid, eksprimira pod regulacijskim upravljanjem endogenog glodarskog MHC II-a-promotora i regulacijskih elemenata i/ili se druga nukleotidna sekvenca koja kodira kimerni ljudski/glodarski MHC II-B-polipeptid, eksprimira pod regulacijskim upravljanjem endogenog glodarskog MHC II-B-promotora i regulacijskih elemenata.
Therefore, medicaments of the invention facilitate the treatment of inflammatory or obstructive airway diseases because a once daily therapy may be sufficient. 
Dakle, lijekovi iz izuma olakšavaju liječenje upalnih ili opstruktivnih bolesti dišnih puteva, budući da može biti dovoljna terapija jednom dnevno.
A tire (1) as claimed in any one of claims 4-9, characterized in that the triangular openings (8) of a row of triangular openings which are equidistant from the rotational axis of the tire (1) are congruent. 
Guma (1) prema bilo kojem od zahtjeva 1 - 8, naznačena time što su trokutasti otvori (8) u redu trokutastih otvora koji se nalaze na jednakoj udaljenosti od osi rotacije gume (1) jednaki.
Monitoring and control system according to claim 5 or 6, further comprising at least one isolated power supply (918, 948; 1930) for providing power to the multiplexer and/or the at least one measuring transducer (910, 960; 1960), wherein in particular the number of isolated power supplies is equal or less than the number of measuring transducers. 
Sustav za nadgledanje i upravljanje prema patentnom zahtjevu 4 ili 5, naznačen time što nadalje sadrži najmanje jedan izolirani izvor napajanja (918, 948; 1930) za osiguravanje napajanja za multiplekser i/ili najmanje jedan HR P20190989 T1 mjerni pretvornik (910, 960; 1960), pri čemu je naročito broj izoliranih izvora napajanja jednak ili manji od broja mjernih pretvornika.
deletion of an endogenous rat nucleic acid sequence, wherein the deletion ranges from about 5 kb to about 10 kb, from about 10 kb to about 20 kb, from about 20 kb to about 40 kb, from about 40 kb to about 60 kb, from about 60 kb to about 80 kb, from about 80 kb to about 100 kb, from about 100 kb to about 150 kb, from about 150 kb to about 200 kb, from about 200 kb to about 300 kb, from about 300 kb to about 400 kb, from about 400 kb to about 500 kb, from about 500 kb to about 1 Mb, from about 1 Mb to about 1.5 Mb, from about 1.5 Mb to about 2 Mb, from about 2 Mb to about 2.5 Mb, or from about 2.5 Mb to about 3 Mb; 
(c) deleciju sekvence endogene nukleinske kiseline štakora, pri čemu je delecija u rasponu od oko 5 kb do oko 10 kb, od oko 10 kb do oko 20 kb, od oko 20 kb do oko 40 kb, od oko 40 kb do oko 60 kb, od oko 60 kb do oko 80 kb, od oko 80 kb do oko 100 kb, od oko 100 kb do oko 150 kb, od oko 150 kb do oko 200 kb, od oko 200 kb do oko 300 kb, od oko 300 kb do oko 400 kb, od oko 400 kb do oko 500 kb, od oko 500 kb do oko 1 Mb, od oko 1 Mb do oko 1,5 Mb, od oko 1,5 Mb do oko 2 Mb, od oko 2 Mb do oko 2,5 Mb, ili od oko 2,5 Mb do oko 3 Mb;
Therefore, the epoxy compound of the present invention represented by the general formula (2) or salts thereof can be obtained with a high purity by a simple crystallization operation after the reaction of a compound represented by the general formula (3) or salts thereof with a compound represented by the general formula (4). BEST MODE FOR CARRYING OUT THE INVENTION 
(3) u kojoj R' predstavlja vodik ili skupinu niži alkil; n predstavlja cijeli broj od 1 do 6; i X* predstavlja halogen ili skupinu koja uzrokuje reakciju supstitucije poput halogena, sa spojem ili njegovom soli, prikazanim općom formulom (4): u kojoj R* predstavlja piperidinilnu skupinu prikazanu općom formulom (A1):
TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF 
Neki oblici prikazanog izuma odnose se na postupke liječenja metabolički pripadajućih poremećaja.
The lipid particle of claim 12, wherein the particle has a lipid:therapeutic agent mass ratio of from about 5:1 to about 15:1. 
Čestica lipida u skladu s patentnim zahtjevom 8, naznačena time, da čestica ima maseni omjer lipida: terapeutskog sredstva od 5: 1 do 15: 1.
pulsed electrical stimulation. The system of claim 1 further comprising a controller component configured to simultaneously control the range of current supplied by the first and second stimulation components and establishing the upper limit of current of the first component at not greater than the current at the second stimulation component and dynamically adjusting the upper limit simultaneously with adjustment of the second current. 
Sustav sukladno zahtjevu 1 nadalje obuhvaća kontrolnu komponentu konfiguriranu na način da simultano kontrolira opseg struje koja se pruža pomoću prve i druge stimulacijske komponente i uspostavlja gornju granicu struje prve komponente ne višu od struje na drugoj stimulacijskoj komponenti i dimamički prilagođava gornju granicu simultano s prilagođavanjem druge struje.
Composition according to claim 2, wherein the melatonin is at a concentration of 1.5 to 3% w/v with respect to the final composition. 
Pripravak u skladu s patentnim zahtjevom 2, naznačen time što je melatonin u koncentraciji od 1,5 do 3% tež./vol. u odnosu na gotovi pripravak.
A therapeutically effective amount of a lipid particle of claim 7 for use in a method for treating a disease or disorder in a mammal in need thereof, wherein the disease or disorder is selected from the group consisting of a viral infection, a liver disease or disorder, and cancer. 
Čestica lipida u skladu s patentnim zahtjevom 5, naznačena time, da se koristi u postupku liječenja bolesti ili poremećaja, odabranih iz skupine koju čine virusne infekcije, bolesti ili poremećaji jetre 1 raka kod sisavca kojem je to potrebno, pri čemu je poželjno da je sisavac čovjek.